Amneal Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
November 6, 2020 6:10 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.16, $0.04 better than the analyst estimate of $0.12. Revenue for the quarter came in at $519 million versus the consensus estimate of $482.11 million.
Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company... More
